Drug
Alcestobart
Alcestobart: highest development phase Phase 1/2, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| Alcestobart NCT05609370 | Phase 1/2 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer |
Latest
No recent events.
Follow Alcestobart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.